1,213 results on '"Rouleau, Jean L."'
Search Results
2. Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF
3. Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to
4. Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure
5. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction
6. Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI Trial
7. Abstract 18200: Prognostic Importance of Serial NT-proBNP Measurements Following High-Risk Mi: The PARADISE-MI Trial
8. Abstract 16755: Changes in Mid-Regional Pro-Adrenomedullin During Treatment With Sacubitril/Valsartan
9. Abstract 14399: Development of Heart Failure in High-Risk Post-Myocardial Infarction Patients: An Analysis of the Paradise-MI Trial
10. Abstract 13828: Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARADIGM-HF Proteomic Sub-Study
11. Abstract 12701: Safety and Tolerability of Angiotensin Receptor Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Drug Initiation Setting: A Subgroup Analysis of the PARADISE-MI Trial
12. Abstract 12470: Sacubitril/Valsartan in Patients With Heart Failure and Deterioration of Kidney Function to Estimated Glomerular Filtration Rate Less Than 30ml/min/1.73m2: Insights From PARAGON-HF and PARADIGM-HF
13. Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan
14. Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation
15. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy
16. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction
17. Prognostic Impact of Cardiovascular Versus Noncardiovascular Hospitalizations in Heart Failure With Preserved Ejection Fraction: Insights From TOPCAT
18. Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF
19. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function
20. Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial
21. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT
22. Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE
23. Incidence and Outcomes of Pneumonia in Patients With Heart Failure
24. Independent prognostic importance of blood urea nitrogen to creatinine ratio in heart failure
25. Pulmonary Congestion and Left Ventricular Dysfunction after Myocardial Infarction:Insights from the PARADISE-MI Trial
26. Lymphocytopenia During Hospitalization for Acute Heart Failure and Its Relationship With Portal Congestion and Right Ventricular Function
27. Effects of sacubitril/valsartan according to polypharmacy status in PARAGON‐HF.
28. Independent prognostic importance of blood urea nitrogen (BUN) to creatinine ratio in heart failure
29. Abstract 12470: Sacubitril/Valsartan in Patients With Heart Failure and Deterioration of Kidney Function to Estimated Glomerular Filtration Rate Less Than 30ml/min/1.73m 2 : Insights From PARAGON-HF and PARADIGM-HF
30. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial
31. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF
32. Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis
33. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial
34. Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women
35. Abstract 16658: Serum Potassium and Risk of Death in Patients With HFpEF: An Analysis of PARAGON-HF
36. Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan.
37. Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan
38. Calcium channel blocker and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction
39. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial
40. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial
41. Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure
42. Impact of Intubation Time on Survival following Coronary Artery Bypass Grafting: Insights from the Surgical Treatment for Ischemic Heart Failure (STICH) Trial
43. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure
44. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
45. Comparison of Coding of Heart Failure and Comorbidities in Administrative and Clinical Data for Use in Outcomes Research
46. Knowledge about self‐efficacy and outcomes in patients with heart failure and reduced ejection fraction
47. Changes in mid‐regional pro‐adrenomedullin during treatment with sacubitril/valsartan
48. Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with HFrEF and HFpEF
49. Clinical characteristics of HFrEF patients with rare pathogenic variants in DCM ‐associated genes: a subgroup analysis of the PARADIGM‐HF trial
50. Incremental prognostic value of biomarkers in PARADIGM‐HF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.